Cleveland BioLabs and These 4 Stocks Announce Important FDA Updates
Cleveland BioLabs and These 4 Stocks Announce Important FDA Updates
Filed under: Cleveland Drug Treatment
Cleveland BioLabs (NASDAQ:CBLI): The Federal Drug Administration has awarded Orphan Drug Status to Curaxin CBL0102, for treating Hepatocellular Carcinoma, a type of liver Cancer. This disease affects approximately 30 thousand people in the United …
Read more on Wall St. Cheat Sheet
FDA OKs BioLabs for cancer drug research
Filed under: Cleveland Drug Treatment
Cleveland BioLabs Inc. and its subsidiary Incuron LLC have received orphan drug status for a drug under development to treat cancer. The Buffalo company (NASDAQ: CBLI) received the designation from the U.S. Food and Drug Administration for its Curaxin …
Read more on Business First
FDA Grants Orphan Drug Status For Cleveland BioLabs' Hepatocellular …
Filed under: Cleveland Drug Treatment
(RTTNews) – Cleveland BioLabs Inc (CBLI:Quote) Tuesday announced that curaxin CBL0102 or the quinacrine developed by the company in association with its joint venture partner and Bioprocess Capital Ventures has been granted Orphan Drug status by the U …
Read more on RTT News
From Twitter:
Drug treatment centers in Cleveland: By Abby Laughlin Guidance is provided to those who seek for it. This is ac… http://t.co/wbu6LpU9 – by DhitaLenyRafhia (Dhita Leny Rafhia)